Acumen pharmaceuticals to present at the 42nd annual j.p. morgan healthcare conference

Charlottesville, va., jan. 04, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will present at the 42nd annual j.p.
ABOS Ratings Summary
ABOS Quant Ranking